Craif is a molecular diagnostics company harnessing the power of miRNA and machine learning to develop an early detection classifier. Our proprietary miRNA platform and sampling technology enable the capture of low-expression RNA, facilitating the development of assays that accurately predict early-stage cancer. In 2022, Craif launched its miSignal multi-cancer early detection assay in Japan, covering seven cancer types (pancreatic, ovarian, oesophageal, lung, breast, colorectal, and gastric).

Craif USA was established in 2023 to introduce this platform to the US market, with a focus on pancreatic cancer. We are currently enrolling cancer patients and high-risk controls for US population validation of the assay. Craif USA is also developing a portfolio strategy tailored to the unmet clinical needs and competitive landscape of the US.